A senior health ministry official of Indonesia has said that 19 million doses of COVID-19 vaccines in the country's national stockpile have expired this year and 1.5 million more are set to expire next month, as donated shots arrive with a short shelf life, Reuters news agency reported on Wednesday.
Lucia Rizka Andalusia told a parliamentary hearing that of the 19.3 million doses that expired between January and March 2022, 97% were donated.
According to Andalusia, most of the expired doses were AstraZeneca's (LON:AZN) shot and also included Moderna's (Nasdaq:MRNA).
She added that Indonesia would prioritise the distribution of vaccines nearing expiry.
Indonesia receives COVID-19 vaccine donations from the COVAX global vaccine sharing facility and from countries such as Australia and the United States.
I Gede Ngurah Swajaya, a foreign ministry official, told the same hearing that the country will stop receiving donations until April 2022 and tell donating countries that the vaccines donated must carry at least two-thirds of the shelf life.
The GAVI vaccine alliance, which runs COVAX with the World Health Organisation, told Reuters that COVAX "only ships doses that have been accepted by countries with full knowledge of vaccine type, estimated shipment plan and vaccine shelf life".
Indonesia's food and drug agency had said earlier this month that it had extended the expiry dates of several vaccines, including AstraZeneca's and Sinovac's, after reviewing new available data about their efficacy.
Circio Holding and Entos Pharmaceuticals collaborate on circular RNA delivery
AKAGERA Medicines completes first cohort in phase 1 SAD/MAD study of AKG-100
Alzinova AB reports positive final Phase 1b results for ALZ-101 in Alzheimer's
Primrose Bio launches Prima RNApols ExTend RNA polymerase for long-template mRNA manufacturing
Merck's CAPVAXIVE approved by EC for pneumococcal disease prevention
Sanofi secures FDA fast track designation for chlamydia vaccine candidate
Anixa Biosciences secures US patent allowance for ovarian cancer vaccine
Valneva to supply IXCHIQ vaccine for chikungunya outbreak in La Réunion
Everest Medicines' EVM14 IND application receives US FDA approval
Clover Biopharmaceuticals' SCB-1019 IND application receives US FDA approval
Centivax partners with Emery Pharma on universal flu vaccine
Avance Biosciences registers with CLIA program
GSK receives approval from US FDA for Penmenvy 5-in-1 meningitis vaccine
hVIVO secures GBP2m contract for final stage of hMPV characterisation study
EU approves CSL and Arcturus Therapeutics' self-amplifying mRNA COVID-19 vaccine